$16.57
2.09% today
Nasdaq, Feb 28, 04:58 pm CET
ISIN
IL0011316309
Symbol
MDWD
Sector
Industry

MediWound Ltd. Stock price

$16.23
-4.00 19.77% 1M
-3.87 19.25% 6M
-1.57 8.82% YTD
+1.55 10.56% 1Y
-0.50 2.99% 3Y
-0.43 2.58% 5Y
-37.74 69.93% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
+0.25 1.56%
ISIN
IL0011316309
Symbol
MDWD
Sector
Industry

Key metrics

Market capitalization $175.06m
Enterprise Value $136.69m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 6.93
P/S ratio (TTM) P/S ratio 8.88
P/B ratio (TTM) P/B ratio 5.11
Revenue growth (TTM) Revenue growth -21.01%
Revenue (TTM) Revenue $19.72m
EBIT (operating result TTM) EBIT $-17.18m
Free Cash Flow (TTM) Free Cash Flow $-19.98m
Cash position $45.56m
EPS (TTM) EPS $-2.90
P/E forward negative
P/S forward 8.67
EV/Sales forward 6.77
Short interest 8.89%
Show more

Is MediWound Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

MediWound Ltd. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a MediWound Ltd. forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a MediWound Ltd. forecast:

Buy
100%

Financial data from MediWound Ltd.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
20 20
21% 21%
100%
- Direct Costs 17 17
24% 24%
88%
2.45 2.45
78% 78%
12%
- Selling and Administrative Expenses 11 11
0% 0%
53%
- Research and Development Expense 7.70 7.70
8% 8%
39%
-16 -16
100% 100%
-80%
- Depreciation and Amortization 1.43 1.43
15% 15%
7%
EBIT (Operating Income) EBIT -17 -17
88% 88%
-87%
Net Profit -28 -28
126% 126%
-142%

In millions USD.

Don't miss a Thing! We will send you all news about MediWound Ltd. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MediWound Ltd. Stock News

Neutral
GlobeNewsWire
3 days ago
Findings in Burns Journal confirm NexoBrid's superiority over standard of care in pediatric patients with deep thermal burns NexoBrid is approved for pediatric use in the U.S., E.U. and Japan YAVNE, Israel, Feb. 25, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd.
Neutral
GlobeNewsWire
4 days ago
YAVNE, Israel, Feb. 24, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive Officer Ofer Gonen will present a corporate overview at the upcoming 45th Annual TD Cowen Health Care Conference, taking place in Boston, MA on Wednesday, March 5, 2025, at 11:50 AM ET.
Positive
Reuters
16 days ago
MediWound , an Israeli developer of products to treat burns and wounds using non-surgical tissue repair, said on Wednesday it was starting a Phase III trial for its treatment for venous leg ulcers.
More MediWound Ltd. News

Company Profile

MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in 2001 and is headquartered in Yavne, Israel.

Head office Israel
CEO Ofer Gonen
Employees 100
Founded 2000
Website www.mediwound.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today